Drugs / Anrukinzumab
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT00340327 | Jun 2006 → Jul 2007 | — | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT00339872 | Feb 2006 → Apr 2007 | asthma | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 23 trials · 3 missed | ||||||
| Phase 2 | NCT01284062 | Mar 2011 → Apr 2013 | ulcerative colitis | Pfizer | Completed | Missed primary |
| Phase 2 | NCT00410280 | Mar 2007 → May 2008 | asthma | Pfizer | Completed | Missed primary |
| Phase 2 | NCT00425061 | Feb 2007 → Aug 2008 | asthma | Pfizer | Completed | Missed primary |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Anrukinzumab | “Anrukinzumab, an anti-interleukin 13 monoclonal antibody, in active UC: efficacy and safety from a phase IIa randomised multicentre study.” PMID 25567115 ↗ Jan 2015 |
| Known as | IMA-638 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00339872 ↗ |
| Action | Inhibit | “anti-IL-13 monoclonal antibodies” PMID 21057005 ↗ Nov 2010 |
| Modality | Monoclonal antibody | “anti-IL-13 monoclonal antibodies” PMID 21057005 ↗ Nov 2010 |
| Route | Subcutaneous | “IMA-638 Administered Subcutaneously” NCT00339872 ↗ |
| Target | IL13 | “anti-IL-13 monoclonal antibodies” PMID 21057005 ↗ Nov 2010 |